Compare Allegion PLC (ALLE) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Medtronic PLC — how do they compare? Allegion PLC trades at $165.82 (market cap $14.32B), while Medtronic PLC trades at $90.62 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 8.1× Allegion PLC's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| ALLE | MDT | |
|---|---|---|
Market Cap | $14.32B | $116.07B |
Sector | Industrials | Health |
52-Week High | $179.77 | $105.35 |
52-Week Low | $125.65 | $73.75 |
Enterprise Value | $16.03B | $134.82B |
Dividend Yield | 1.26% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALLE trades at $166.18, up 0.39% on the day, showing strong momentum following better-than-expected Q2 2026 earnings. The stock demonstrates robust fundamentals with 15.36% net income margin and 33.73% ROE, though recent quarters show mixed earnings performance. Technical indicators suggest bullish momentum with the current price near resistance levels. Recent institutional buying and positive analyst coverage highlight growing confidence in the security products provider's growth trajectory.
Outlook remains positive with raised 2026 guidance and strong Americas segment performance driving optimism. Investment opportunity lies in continued margin expansion and market share gains, while risks include international segment weakness and rising input costs. The stock trades above consensus price target but offers potential upside to high target of $170.
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
